A study on the correlates of habit-, reward-, and fear-related motivations in alcohol use disorder.


Journal

CNS spectrums
ISSN: 1092-8529
Titre abrégé: CNS Spectr
Pays: United States
ID NLM: 9702877

Informations de publication

Date de publication:
12 2019
Historique:
pubmed: 28 3 2019
medline: 26 8 2020
entrez: 28 3 2019
Statut: ppublish

Résumé

We assessed self-reported drives for alcohol use and their impact on clinical features of alcohol use disorder (AUD) patients. Our prediction was that, in contrast to "affectively" (reward or fear) driven drinking, "habitual" drinking would be associated with worse clinical features in relation to alcohol use and higher occurrence of associated psychiatric symptoms. Fifty-eight Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) alcohol abuse patients were assessed with a comprehensive battery of reward- and fear-based behavioral tendencies. An 18-item self-report instrument (the Habit, Reward and Fear Scale; HRFS) was employed to quantify affective (fear or reward) and non-affective (habitual) motivations for alcohol use. To characterize clinical and demographic measures associated with habit, reward, and fear, we conducted a partial least squares analysis. Habitual alcohol use was significantly associated with the severity of alcohol dependence reflected across a range of domains and with lower number of detoxifications across multiple settings. In contrast, reward-driven alcohol use was associated with a single domain of alcohol dependence, reward-related behavioral tendencies, and lower number of detoxifications. These results seem to be consistent with a shift from goal-directed to habit-driven alcohol use with severity and progression of addiction, complementing preclinical work and informing biological models of addiction. Both reward-related and habit-driven alcohol use were associated with lower number of detoxifications, perhaps stemming from more benign course for the reward-related and lack of treatment engagement for the habit-related alcohol abuse group. Future work should further explore the role of habit in this and other addictive disorders, and in obsessive-compulsive related disorders.

Identifiants

pubmed: 30915941
pii: S1092852918001554
doi: 10.1017/S1092852918001554
pmc: PMC6885012
mid: EMS84190
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

597-604

Références

Pers Individ Dif. 2017 Oct 1;116:73-85
pubmed: 28974825
J Stud Alcohol Drugs. 2016 Mar;77(2):354-61
pubmed: 26997195
Annu Rev Psychol. 2016;67:23-50
pubmed: 26253543
Biol Psychiatry. 2017 Dec 1;82(11):847-856
pubmed: 28673442
J Nerv Ment Dis. 1980 Jan;168(1):26-33
pubmed: 7351540
Behav Brain Res. 2009 Apr 12;199(1):89-102
pubmed: 18950658
PLoS One. 2014 Jan 06;9(1):e84560
pubmed: 24400099
Lancet. 2009 Jun 27;373(9682):2223-33
pubmed: 19560604
Addict Behav. 2006 Mar;31(3):399-403
pubmed: 15964149
Neuropsychobiology. 2014;70(2):122-31
pubmed: 25359492
Compr Psychiatry. 2017 Oct;78:25-30
pubmed: 28779593
Neurosci Biobehav Rev. 2014 Nov;47:281-94
pubmed: 25193245
CNS Spectr. 2017 Jun;22(3):295-304
pubmed: 28065178
Q J Exp Psychol B. 2002 Oct;55(4):331-48
pubmed: 12350285
Addiction. 2019 Jun;114(6):1095-1109
pubmed: 30133930
Braz J Psychiatry. 2004 May;26 Suppl 1:S3-6
pubmed: 15729435
Health Psychol Rev. 2015;9(3):277-95
pubmed: 25207647
Transl Psychiatry. 2013 Dec 17;3:e337
pubmed: 24346135
Adv Alcohol Subst Abuse. 1990;9(1-2):47-66
pubmed: 2165735
Annu Rev Psychol. 2016;67:289-314
pubmed: 26361052
Alcohol Clin Exp Res. 2013 Sep;37(9):1441-50
pubmed: 23578176
Can J Psychiatry. 2016 Mar;61(3):145-53
pubmed: 27254089
Neurotox Res. 2008 Oct;14(2-3):185-9
pubmed: 19073425
Addiction. 2006 Sep;101 Suppl 1:104-10
pubmed: 16930166
Neurosci Biobehav Rev. 2010 Nov;35(2):334-44
pubmed: 19941895
J Stud Alcohol Drugs. 2009 Sep;70(5):689-99
pubmed: 19737493
Front Psychol. 2017 Apr 24;8:622
pubmed: 28484414
Addict Biol. 2018 Jan;23(1):379-393
pubmed: 28111829
Alcohol Clin Exp Res. 2016 Jul;40(7):1380-9
pubmed: 27223341
J Affect Disord. 2014 Feb;155:104-9
pubmed: 24238871

Auteurs

Marcelo Piquet-Pessôa (M)

Obsessive, Compulsive, and Anxiety Spectrum Research Program, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Samuel R Chamberlain (SR)

Department of Psychiatry, University of Cambridge, Cambridge, UK.
Department of Psychiatry, University of Cambridge, and Cambridge & Peterborough NHS Foundation Trust (CPFT), Cambridge, UK.

Rico S C Lee (RSC)

Brain & Mental Health Laboratory, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Victoria, Australia.

Gabriela M Ferreira (GM)

Obsessive, Compulsive, and Anxiety Spectrum Research Program, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Marcelo S Cruz (MS)

Substance Abuse Research Program, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Ana P Ribeiro (AP)

Substance Abuse Research Program, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Gabriela B de Menezes (GB)

Obsessive, Compulsive, and Anxiety Spectrum Research Program, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Lucy Albertella (L)

Brain & Mental Health Laboratory, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Victoria, Australia.

Murat Yücel (M)

Brain & Mental Health Laboratory, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Victoria, Australia.

Leonardo F Fontenelle (LF)

Obsessive, Compulsive, and Anxiety Spectrum Research Program, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Brain & Mental Health Laboratory, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Victoria, Australia.
D'Or Institute for Research and Education, Rio de Janeiro, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH